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AbstrAct
Objectives The optimal method of identifying people with 
asthma from electronic health records in primary care 
is not known. The aim of this study is to determine the 
positive predictive value (PPV) of different algorithms using 
clinical codes and prescription data to identify people with 
asthma in the United Kingdom Clinical Practice Research 
Datalink (CPRD).
Methods 684 participants registered with a general 
practitioner (GP) practice contributing to CPRD between 
1 December 2013 and 30 November 2015 were selected 
according to one of eight predefined potential asthma 
identification algorithms. A questionnaire was sent to 
the GPs to confirm asthma status and provide additional 
information to support an asthma diagnosis. Two study 
physicians independently reviewed and adjudicated the 
questionnaires and additional information to form a gold 
standard for asthma diagnosis. The PPV was calculated for 
each algorithm.
results 684 questionnaires were sent, of which 494 
(72%) were returned and 475 (69%) were complete and 
analysed. All five algorithms including a specific Read code 
indicating asthma or non-specific Read code accompanied 
by additional conditions performed well. The PPV for 
asthma diagnosis using only a specific asthma code was 
86.4% (95% CI 77.4% to 95.4%). Extra information on 
asthma medication prescription (PPV 83.3%), evidence 
of reversibility testing (PPV 86.0%) or a combination of 
all three selection criteria (PPV 86.4%) did not result in 
a higher PPV. The algorithm using non-specific asthma 
codes, information on reversibility testing and respiratory 
medication use scored highest (PPV 90.7%, 95% CI (82.8% 
to 98.7%), but had a much lower identifiable population. 
Algorithms based on asthma symptom codes had low 
PPVs (43.1% to 57.8%)%).
conclusions People with asthma can be accurately 
identified from UK primary care records using specific 
Read codes. The inclusion of spirometry or asthma 
medications in the algorithm did not clearly improve 
accuracy.
Ethics and dissemination The protocol for this research 
was approved by the Independent Scientific Advisory 
Committee (ISAC) for MHRA Database Research (protocol 
number15_257) and the approved protocol was made 
available to the journal and reviewers during peer review. 
Generic ethical approval for observational research using 
the CPRD with approval from ISAC has been granted by 
a Health Research Authority Research Ethics Committee 
(East Midlands—Derby, REC reference number 05/
MRE04/87). The results will be submitted for publication 
and will be disseminated through research conferences 
and peer-reviewed journals.
bAckgrOund
Asthma is one of the most common chronic 
diseases, with an estimated prevalence of 
241 million people worldwide with asthma.1 
The UK has one of the highest asthma prev-
alence and mortality rates in Europe.2 3 The 
disease is a significant burden to the National 
Health Service, with 5.4 million people 
receiving treatment and approximately 
65 000 hospital admissions yearly.4 Cough, 
wheeze, breathlessness and chest tightness 
are its core symptoms5 but it has a wide variety 
of different presentations.6
Electronic health records (EHR) have been 
adopted worldwide, facilitating the construc-
tion of large population-based patient 
databases that have become available over the 
last decades for epidemiological research.7 
Validation of diagnoses or outcomes based on 
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Research
strengths and limitations of this study
 ► This study describes algorithms to identify people 
with asthma from  Clinical Practice Research 
Datalink, a large electronic health records database, 
and measures the positive predictive value of those 
algorithms.
 ► Supporting information, including outpatient referral 
letters, other emergency department discharge 
letters, airflow measurements and radiography 
records were used to identify patients with asthma 
and calculate the test measures.
 ► The gold standard to calculate a positive predictive 
value (general practitioner  (GP) questionnaire and 
review by study physicians) is not absolute, even 
though information from secondary care was used.
 ► GPs of patients with complicated medical histories 
could be less likely to return the questionnaire, but 
remuneration makes this less likely.
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codes recorded in EHRs is required because their accu-
racy is uncertain, and this may affect the reliability and 
validity of subsequent observational studies. The quality 
of studies generated from EHRs may be debatable unless 
their data are validated for specific research purposes.8–11
The diagnosis of asthma relies on clinical judgement 
based on a combination of patient history, physical exam-
ination and confirmation of the variability or reversibility 
of airflow obstruction using airflow measurements. This 
can make it difficult to assess the accuracy of asthma 
diagnoses in EHR-based epidemiological studies as 
some symptoms and airflow measurements may not be 
recorded. In addition, individuals affected by asthma can 
vary greatly in their presentation and symptoms are some-
times similar to other respiratory diseases such as chronic 
obstructive pulmonary disease (COPD).12 13
The aim of this study was to test the accuracy of 
different approaches to identifying asthma in the UK 
Clinical Practice Research Datalink (CPRD) using the 
positive predictive value (PPV), by comparing the data-
base records with a gold standard constructed from a 
review by two study physicians based on information 
provided by general practitioners (GPs) of patients with 
asthma.
MEthOds
Dataset
The CPRD is a large UK primary care database containing 
anonymised data on the people registered with primary 
care practices from across the UK. CPRD is representa-
tive of the UK population with regard to age and sex.14 15 
Within CPRD, diagnostic accuracy has been demonstrated 
to be high for many conditions and diseases, including 
COPD.16–19 CPRD contains detailed clinical information 
on diagnoses, prescriptions, laboratory tests, symptoms 
and hospital referrals, in addition to basic sociodemo-
graphic information recorded by the GP. These GPs 
act as primary care providers and gatekeepers for other 
National Health Service services, and information from 
other healthcare providers is also transmitted back to 
the GP. Clinical events and diagnoses are coded as Read 
codes, a dictionary of clinical terms widely used in the UK 
National Health Services by both primary and secondary 
healthcare providers. Validation studies aid to ensure 
credibility and quality of epidemiological studies done in 
CPRD.10
Inclusion criteria
The study population consisted of people who had a 
record for a Read code indicating possible asthma in the 
2 years before the index date (1 December 2015) and who 
were registered in a GP practice meeting CPRD quality 
criteria. The Read code list is included in the supple-
mentary appendix 1  and is available online at http:// 
datacompass. lshtm. ac. uk/ 236/.% 20 The data collection 
was planned before the index test and reference standard 
were performed. This timespan was chosen for several 
reasons: to overcome potential changes in quality of 
asthma diagnosis and recording over time; to reduce the 
chance that the database records were out of date; and 
to ensure the medical records were still available to GPs. 
People were identified at random based on one of eight 
predefined algorithms exclusively, which means that we 
populated the algorithm resulting in the smallest popu-
lation first and subsequently removed these people from 
the cohort, to prevent them from also being selected for 
another algorithm. We randomly selected 800 possible 
asthma cases for validation. Of these, 116 asthma cases 
were excluded because their GPs no longer participated 
with CPRD at the time questionnaires were sent to the 
clinicians for validation, as shown in figure 1. Because 
of the changes in CPRD data governance after the start 
of the study it was not possible to select replacement 
patients.
gP questionnaire
CPRD mailed a two-page questionnaire to the GPs of 
the people selected for inclusion as described above, 
requesting confirmation of current asthma diagnosis and 
additional information to support this diagnosis. This 
questionnaire can be found in online supplementary 
appendix 2. The questionnaire was designed to ascertain 
the diagnosis of asthma and verify the date of diagnosis. 
The questions included evidence of reversible airway 
obstruction, current symptoms, smoking history, respi-
ratory comorbidities and Quality Outcome Framework 
(QOF) indicators. QOF is a national financial incentive 
scheme for GPs in the UK encouraging regular disease 
indicator measurement and recording. Asthma is one of 
the included diseases, and its indicators including airflow 
measurements and interference with work and night’s 
rest.20
Specific information available from the medical record 
including spirometry printouts and hospital respira-
tory outpatient letters were also requested. Data were 
encrypted twice to ensure anonymity, between practices 
and CPRD and also from CPRD to researchers. A ques-
tionnaire was considered invalid if it was returned blank 
or every question was answered ‘unknown’.
code lists and algorithms
Lists of medical codes (Read codes) deemed as specific 
and non-specific for asthma based on study physicians’ 
opinion were created prior to the start of the study. Read 
codes are a hierarchical clinical coding system that are 
used in general practice in the UK and are entered by the 
GP into a computer program called Vision. Each Read 
code is linked to a specific string of text, which refers 
to a single diagnosis or symptom. These data are then 
uploaded by CPRD after they have been processed and 
quality checked. The list of codes used for specific or defi-
nite asthma codes and non-specific or probable asthma 
codes can be found in online supplementary appendix 1.
Combinations of Read code lists, evidence of revers-
ibility testing and respiratory medication use were used to 
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Figure 1 Study population. GP, general practitioner.
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make up the eight algorithms. The first four algorithms 
required a specific asthma diagnosis code, with the first 
three requiring additional documentation consisting 
of either respiratory medication use and/or evidence 
of reversibility testing. The fifth algorithm required a 
non-specific asthma code and additional documentation 
of both respiratory medications and reversibility testing; 
the last three algorithms required respiratory symptom 
codes indicating asthma symptoms with additional infor-
mation. The presence of spirometry for inclusion in an 
algorithm was based on the existence of a specific spirom-
etry Read code in the records rather than an examination 
of said spirometry, although where spirometry traces were 
provided as part of the additional information, they were 
examined. Evidence of reversibility testing only refers 
to whether airflow measurements or trial of treatment 
was done, and does not reflect the results of these tests. 
Respiratory medication use was defined as at least two 
prescriptions of asthma medication for inhaled asthma 
therapy (short-acting beta-agonists, long-acting beta-ago-
nists and inhaled corticosteroids) within 365 days of each 
other, within the 2 years before the index date. From the 
expected most specific to most sensitive, the eight algo-
rithms were constructed as follows:
1. Specific asthma Read code + evidence of reversibility 
testing (spirometry, variable peak expiratory flow rate 
or trial of treatment) + respiratory medications
2. Specific asthma code + evidence of reversibility 
testing
3. Specific asthma code + respiratory medications
4. Specific asthma code only
5. Non-specific asthma code + evidence of reversibility 
testing + respiratory medications
6. Asthma symptoms (wheeze, breathlessness, chest 
tightness, cough) + evidence of reversibility testing + 
respiratory medications
7. Asthma symptoms + evidence of reversibility testing
8. Asthma symptoms + respiratory medications
Primary outcome
The primary outcome was confirmation of a diagnosis of 
asthma in each of the eight predefined algorithms. The 
gold standard for the diagnosis of asthma was the adjudi-
cated asthma status agreed by the two study physicians, a 
respiratory physician and a GP who reviewed all question-
naires and evidence from the patient’s GP independently. 
The reviewers were blinded to the code lists/algorithm. 
Where opinion differed, the cases were discussed and 
agreement was reached by consensus. The reviewing 
physicians did not know with which algorithm a person 
was selected.
statistical analysis
The PPV was calculated using the proportion of cases 
identified by each algorithm that were confirmed as 
actual cases by the study physicians through a review of 
the questionnaire and supporting evidence. All analyses 
were conducted using Stata V. 14.0.
A patient could contribute only to a single algorithm 
for the main analysis. In the post hoc analysis, individuals 
could be placed into multiple algorithms where possible 
to reduce the CI. The PPV in this analysis was calcu-
lated for all individuals who had a specific asthma code 
compared with those with a specific asthma code and 
additional information. We also performed a sensitivity 
analysis to check whether the age and sex for patients 
whose questionnaire was returned were similar to the 
age and sex of those patients whose questionnaire was 
not sent out or were there was no response. The study 
protocol is included in online supplementary appendix 3.
sample size calculation
As there were 116 patients that could not be evaluated, 
precision was expected to be slightly lower than in the 
original sample size calculations. However, a percentage 
difference in PPV of 0.13 is demonstrable with a sample 
size of 60 per algorithm (assuming PPV=0.85, α=0.05 and 
power=0.8).
rEsults
A total of 800 potential asthma cases were selected for 
validation, of which 116 cases had migrated out of the 
database at the time the questionnaires were sent. Of 
the remaining 684 cases, there were 494 returned ques-
tionnaires. Nineteen of the returned questionnaires 
were considered invalid. Thus, 475 valid questionnaires 
were received, which yielded a response rate of 69.4% 
(475/684) using the practices that could have answered 
as denominator, as shown in figure 1. The time interval 
between the mailing of questionnaires and the review by 
the study physicians varied, but none of these time inter-
vals was greater than 8 months.
The baseline characteristics of the 475 patients with 
valid returned questionnaires are shown in table 1. 
The study populations were mostly middle aged, never 
smokers and female. There were 97 individuals whose 
smoking status was not filled in on the questionnaire. 
Differences in the majority of characteristics were seen 
among most algorithms.
The PPVs of the eight algorithms are displayed in 
table 2.
The PPVs of algorithms containing specific or non-spe-
cific asthma codes in algorithms 1–5 (ranging from 83.3% 
to 90.7%) are markedly higher than the PPVs of the algo-
rithms based on asthma symptoms (ranging from 43.1% 
to 57.8%). The combination of a specific code and asthma 
medication prescription and/or evidence of reversibility 
testing (PPV varies from 83.3% to 86.8%) did not consid-
erably increase the PPV compared with a specific asthma 
code alone (PPV 86.4%). The highest PPV was found 
in the fifth algorithm combining a non-specific asthma 
code with evidence of reversibility testing and asthma 
medication use. However, the total number of patients 
identifiable with this algorithm (n=33 280) was less than 
one-fifth of those identifiable by the fourth algorithm 
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Table 2 The positive predictive value (PPV) and proportion of patients diagnosed with chronic obstructive pulmonary disease 
within each algorithm
Algorithm
Eligible 
population
Questionnaires 
sent out
Valid returned 
questionnaires (n, %)
Confirmed 
asthma cases PPV (95% CI)
Specific asthma code + 
reversibility testing + medication
36 516 92 68 (60) 61 86.8 (78.5 to 95.0)
Specific asthma code + 
reversibility testing
38 796 90 57 (63.3) 51 86.0 (76.7 to 95.3)
Specific asthma code + 
medication
169 574 89 60 (67.4) 51 83.3 (73.6 to 93.0)
Specific asthma code 188 133 84 59 (70.2) 51 86.4 (77.4 to 95.4)
Non-specific asthma code + 
reversibility testing + medication
33 280 78 54 (69.2) 49 90.7 (82.8 to 98.7)
Symptoms + reversibility testing + 
medication
53 117 87 55 (63.2) 32 56.4 (42.8 to 69.9)
Symptoms + reversibility testing 66 477 88 58 (65.9) 26 43.1 (30.0 to 56.2)
Symptoms + medication 190 753 78 64 (82.1) 38 57.8 (45.4 to 70.2)
Medication use was defined as two prescriptions within 365 days. Evidence of reversibility testing does not hold information on the outcome 
of these tests.
Figure 2 PPV as diagnosed by the patient's own GP, and agreement between the study physicians. GP, general practitioner; 
PPV, positive predictive value.
consisting of a specific asthma code alone (n=188 133) 
in the chosen time period. We have not examined the 
validity of a non-specific asthma code alone.
A post hoc analysis was performed where individuals 
were placed in every algorithm they qualified for. In this 
analysis, we found that the use of additional information 
on evidence of reversibility testing or medication in an 
algorithm with a specific asthma code again did not mean-
ingfully increase the PPV. The PPV for all individuals who 
had a specific asthma code and information on revers-
ibility testing or medication was 86.7% (95% CI 83.3% to 
90.1%), and the PPV for individuals with only a specific 
asthma code was 86.4% (95% CI 83.0% to 89.7%).
When validating the record of possible asthma with a 
gold standard based on the study physicians’ view of extra 
evidence provided by the GP, the PPV slightly improved 
across all algorithms. Figure 2 demonstrates the PPV of 
the different algorithms as diagnosed by the patient’s own 
GP and the study physicians (overall κ=0.81).
There was no considerable difference in age or sex 
between patients whose questionnaire was returned 
and patients whose questionnaire was not sent out (age: 
p=0.74, sex: p=0.73) or were there was no response (age 
p=0.50, sex p=0.13) using χ² tests.
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dIscussIOn
We tested the accuracy of eight algorithms to identify 
asthma within CPRD using a gold standard constructed 
using a consensus of the two study physicians. The algo-
rithm with the highest PPV consisted of a combination 
for non-specific asthma codes, evidence of reversibility 
testing and multiple asthma prescriptions within 1 year 
(PPV 90.7, 95% CI 82.8 to 0.98.7) followed by a combi-
nation for specific asthma codes, evidence of reversibility 
testing and multiple asthma prescriptions within 1 year. 
The CI of this PPV overlaps with the CIs of each of the 
PPVs of the first four algorithms based on specific asthma 
codes, so the difference might be due to chance alone. 
The algorithm with the lowest PPV consisted of asthma 
symptoms and evidence of reversibility testing (PPV 0.43, 
95% CI 0.30 to 0.55). The results of this validation study 
suggest that the clinical code-based algorithms that use 
asthma codes to identify asthma cases have high PPVs 
(between 0.84 and 0.91). In this dataset, a specific asthma 
code algorithm alone appears sufficient to identify 
current patients with asthma from CPRD. As the addi-
tional requirements of medication use and evidence of 
reversibility testing do not appear to significantly increase 
the PPV, the total number of individuals who can poten-
tially be included in a study increases from 33 280 to 
188 133 in the chosen time period (1 December 2013 to 
30 November 2015). The total identifiable population of 
people living with asthma is thus much larger when only 
using a specific asthma code for identification.
comparison with previous studies
Validity of asthma codes in EHRs can be assessed by 
comparison to three different sets of gold standard: 
comparison to an external database, questionnaire and 
manual review by a clinician. This validation study uses 
questionnaires and manual review. Our gold standard 
consisted of the agreement of the study respiratory physi-
cian and study GP, both of whom were experienced with 
CPRD.
Previous studies which validated asthma in other EHR 
databases used manual review by clinicians to validate 
asthma in EHR and all reported at least one algorithm 
with a PPV above 85%.21–26 In contrast with this study, the 
best results in previous studies arose when combining 
diagnostic data and prescription data.
The CPRD has provided anonymised primary care 
records for public health research since 1987; research 
was always a focus of interest when it was established. 
GPs contributing to the CPRD have been trained on how 
to record data for research use. As a consequence, data 
quality may be higher than in many other databases, in 
which research is only a secondary product.
strengths of this study
This study has several strengths. First, we were able to 
investigate the accuracy of eight predefined different algo-
rithms and how they perform in identification of people 
with asthma in CPRD, as well as the accuracy of the actual 
GP diagnosis of asthma using additional information 
provided. Second, we included supporting information 
such as outpatient referral letters, other emergency 
department discharge letters, airflow measurements 
and radiography records. Finally, we validated asthma 
diagnoses found in CPRD, which is a primary care data-
base that is extensively used for studying different health 
outcomes in epidemiological research. This primary 
care database provides health and medication history of 
millions of patients. A validated definition in CPRD of 
asthma allows for informed healthcare service planning 
by increasing the reliability of evidence generated from 
observational studies.
limitations of this study
This study has limitations to consider. The gold standard 
consisting of a GP questionnaire and review by study 
physicians is not absolute, even if we mitigated this with 
additional information from secondary care. A GP can 
look in the EHR to see if a specific diagnosis has been 
recorded for a specific patient when asked. This may 
lead to an overestimation of the PPV, but there is no suit-
able practical alternative. Ideally, airflow measurements 
and reversibility testing on each potential patient would 
form the optimal gold standard, but this would not be 
feasible in this setting due to cost. The overall number of 
questionnaires sent out (n=684) was less than requested 
(n=800) as some patients and practices were no longer 
part of CPRD and could not be contacted. However, the 
precision of PPV estimates was not substantially reduced.
Although practices contributing to CPRD are a sample 
of all practices in the UK, they are considered represen-
tative of the UK population with few patients opting out 
of contributing data, and is therefore unlikely to bias the 
results.14
GPs of patients with complicated medical histories 
could be less likely to return the questionnaire. The GPs 
were remunerated for their participation however, which 
is likely to have reduced the chance of this happening. 
Within the returned questionnaires, the amount of 
missing data was low, which suggests reasonable data 
quality. In addition, only living patients were assessed, 
as GPs no longer have access to the patient records after 
death. This excludes the records of the deceased patients 
and could result in survival bias. Patients had to be alive 
to be included, but it is unlikely that coding would differ 
between living and deceased individuals. If deceased 
people had died of asthma, the PPV in this study would 
be underestimated. Our findings are likely to be gener-
alisable to other UK primary care databases using Read 
coding, but these would ideally still require validation. 
Databases using other coding systems may need to validate 
different algorithms to identify asthma, which might limit 
the generalisability of our findings. Another limitation 
is that we were not able to assess the negative predictive 
value of asthma diagnoses in CPRD because we evaluated 
only patients belonging to one of the eight algorithms. 
We could not calculate the specificity or sensitivity as we 
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had preselected our population of possible asthma cases. 
We also assumed the validity of asthma diagnoses would 
not be different between common and less frequent Read 
codes and the quality of recording would also be compa-
rable for pragmatic reasons. However, the less commonly 
used codes will by definition identify a smaller proportion 
of all patients with asthma, so the validity we report will 
apply to the majority of patients.
cOnclusIOn
We have successfully estimated the PPV of several different 
algorithms to identify people with asthma in CPRD. The 
PPVs for specific asthma Read codes alone and non-spe-
cific ones in a combination with additional evidence were 
all greater than 0.84. A specific asthma code algorithm 
alone appears to be the most practical approach to iden-
tify patients with asthma in CPRD (PPV=0.86; 95% CI 0.77 
to 0.95). Diagnoses were confirmed in a high proportion 
of patients with specific asthma codes, suggesting that 
epidemiological asthma research conducted using CPRD 
data can be conducted with reasonably high validity.
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